Prospective Evaluation of Minimal Residual Disease in the Phase II FORTE Trial: a Head-to-head Comparison Between Multiparameter Flow Cytometry and Next-Generation Sequencing
ECLINICALMEDICINE(2023)
Key words
Newly diagnosed multiple myeloma (NDMM),Minimal residual disease (MRD),Multiparameter flow cytometry (MFC),Next-generation sequencing (NGS),Autologous stem-cell transplantation (ASCT)
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined